Nanobiotix Finalizes $100M Global Offering with Full Over-Allotment Exercise
NBTX has more than doubled off its 52-week low of $3.64.
Summary
Nanobiotix has completed its global offering, raising $100 million after underwriters fully exercised their over-allotment option, securing funding into 2029.
Key Events · Financing and Capital Events · NBTX
-
Offering Finalized
Underwriters fully exercised their over-allotment option for the global offering, increasing the total capital raised.
-
Capital Raised
The global offering, including the over-allotment, generated approximately $100 million in gross proceeds for the company.
-
Cash Runway Extended
The company expects these proceeds, combined with existing cash, to fund operations into 2029.
-
Pricing Details
The offering was priced at $38.98 per ADS, which represents a 14.92% discount to the volume-weighted average price of ordinary shares on Euronext Paris.
Analysis · NBTX · Life Sciences
This filing confirms the full exercise of the underwriters' over-allotment option, increasing the total gross proceeds from the global offering to $100 million. This capital raise, though dilutive and priced at a discount, significantly extends Nanobiotix's cash runway into 2029, providing crucial financial stability for its clinical development programs. The full exercise of the option indicates strong investor demand for the offering.
At the time of this filing, NBTX was trading at $41.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $3.64 to $57.14. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.